Search Medical Condition
Please enter condition
Please choose location

Lafayette, Indiana Clinical Trials

A listing of Lafayette, Indiana clinical trials actively recruiting patient volunteers.

RESULTS

Found (50) clinical trials

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

This study is a randomized, open-label, international, multi-center, phase 2 study in patients with Heregulin-positive NSCLC that have progressed following no more than three systemic therapies for locally advanced or metastatic disease, of which one must have been an anti-PD-1 or anti-PD-L1 therapy. All patients will initially be screened for ...

Phase

0.69 miles

Learn More »

Biorepository: Indiana Health Study

Study Aim: The purpose of this study is to create an extensively annotated bio-repository platform for hypothesis-driven research that will lead to advancements in the diagnosis, treatment and prevention of diseases common to the population of Indiana. The first phase of this research platform will be created by collecting blood ...

Phase N/A

0.69 miles

Learn More »

This study is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with ACP-196 in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Arms Assigned Interventions Active Comparator: Obinutuzumab in Combination with Chlorambucil Obinutuzumab IV infusions will be administered over ...

Phase

0.69 miles

Learn More »

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

This is a prospective, multicenter, open-label study assessing the efficacy and safety of RBX2660 as an adjunct to antibiotics for the treatment of recurrent CDI. The primary assessments for this study are (i) to assess efficacy as the absence of CDI diarrhea without the need for retreatment with C. difficile ...

Phase

1.04 miles

Learn More »

Rituximab Bendamustine Hydrochloride and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

OBJECTIVES Primary To determine whether the addition of bortezomib (RBV) to an induction regimen of rituximab-bendamustine hydrochloride (RB) improves progression-free survival (PFS) compared to RB alone in patients 60 years of age with previously untreated mantle cell lymphoma. To determine whether the addition of lenalidomide to a consolidation regimen of ...

Phase

1.04 miles

Learn More »

Efficacy and Safety of Nipent Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Chronic Lymphocytic Leukemia (CLL) is the most common form of adult leukemia in the U.S. Recent experience with Nipent in conjunction with Rituxan has shown that this combination is well tolerated and is clinically promising. It is expected that the addition of Cytoxan in patients with previously untreated CLL and ...

Phase

1.04 miles

Learn More »

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

This is a phase 3 randomized, placebo controlled study to evaluate the safety and anti-tumor activity of Avelumab in combination with standard of care chemoradiation (SoC CRT) versus SoC CRT alone in front-line treatment of patients with locally advanced head and neck cancer.

Phase

1.04 miles

Learn More »

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

While adjuvant endocrine therapy (ET) is effective in reducing risk of recurrence in patients with hormone receptor (HR)-positive early breast cancer (EBC), recurrences are still common, especially in patients with unfavorable clinical, pathological and/or molecular features. Ribociclib, a CDK4/6 inhibitor, demonstrated clinical efficacy with tolerable toxicity when added to ET ...

Phase

1.04 miles

Learn More »

NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors Lymphomas or Multiple Myeloma

PRIMARY OBJECTIVES: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced ...

Phase

1.04 miles

Learn More »

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

OBJECTIVES Primary To compare whether the addition of one year of everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR)-positive, and human epidermal growth factor receptor (HER)2-negative breast cancer. Secondary To compare whether the addition of one year of ...

Phase

1.04 miles

Learn More »